Capricor Therapeutics (CAPR) Cash from Operations (2010 - 2026)

Capricor Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 29254891.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 354.73% year-over-year to 29254891.0; the TTM figure through Mar 2026 stood at 92632632.0 (down 105.12% YoY), while the FY2025 annual figure was 69811261.0, down 74.55% from the prior year.
• Cash from Operations for Q1 2026 stood at 29254891.0, down from 23566743.0 in the prior quarter.
• The five-year high for Cash from Operations was 24046566.0 in Q1 2022, with the low at 29254891.0 in Q1 2026.
• The 5-year median for Cash from Operations is 9417750.0 (2023), against an average of 9396576.59.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations surged 822.26% in 2022, then tumbled 407.2% in 2025.
• Capricor Therapeutics' Cash from Operations stood at 6902052.0 in 2022, then plunged by 67.98% to 11594052.0 in 2023, then slipped by 27.62% to 14796329.0 in 2024, then tumbled by 59.27% to 23566743.0 in 2025, then slipped by 24.14% to 29254891.0 in 2026.
• Business Quant data shows CAPR's Cash from Operations at 29254891.0 in Q1 2026, 23566743.0 in Q4 2025, and 19688787.0 in Q3 2025.